PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients

References

Page 1

	Year	Citations
Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong, Science	1987	11.6K
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, New England Journal of Medicine	2001	11.4K
<i>PTEN</i> , a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer Jing Li, Clifford Yen, Danny Liaw, Science	1997	4.8K
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer Charles L. Vogel Journal of Clinical Oncology	2002	2.9K
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease Melody Cobleigh, Charles L. Vogel, Debu Tripathy, Journal of Clinical Oncology	1999	2.8K
Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Hyun‐Soo Cho, Karen Mason, Kasra X. Ramyar, Nature Extracellular RegionProtein SecretionSignal TransductionProtein FunctionNatural Sciences	2003	1.6K
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin) Yen‐Yu Lu, Xiaolin Zi, Yuqing Zhao, JNCI Journal of the National Cancer Institute	2001	885
Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Alicia M. Viloria Petit, Janusz Rak, Mien‐Chie Hung, PubMed	1997	841
THE IMPACT OF NATIONAL CANCER ACT Frankie A. Holmes, Ronald S. Walters, Richard L. Theriault, JNCI Journal of the National Cancer Institute	1991	802
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Jordi Codony‐Servat, Joan Albanell, Federico Rojo, PubMed Her2 Ectodomain CleavageBreast OncologyBiochemistryMedicineNatural Sciences	2001	775

Page 1